Figure 12.

Effect of GL on the MAPK and NF-κB signaling pathways in murine BMDCs. The cells were treated with PBS (-, control) or GL (plus, 200 μg/ml) at the indicated time points. (A) Cell lysates were prepared, and phosphorylation of total (t)-ERK, phosphorylated (p)-ERK, t-JNK, p-JNK, t-p38 and p-p38ERK1/2 was analyzed by western blotting. (B) Nuclear and cytosolic extracts in BMDCs were prepared and detected with p65 and IκBα antibody by western blotting. (C, D) BMDCs were pretreated with NF-κB inhibitor (BAY 11-7082, 20 μM), JNK inhibitor (SP600125, 20 μM), p38 MAPK inhibitor (SB203580, 20 μM), or ERK1/2 inhibitor (U0126, 20 μM), followed by treatment with GL (200 μg/ml) for 30 min, and then IL-12p70 and IL-6 secretion in supernatant were quantified by ELISA. The data represent three independent experiments. The mean ± SD of the results from three independent experiments is shown. *P < 0.05; **P < 0.01.